Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
3.510
+0.450 (14.71%)
At close: May 13, 2025, 4:00 PM
3.480
-0.030 (-0.85%)
Pre-market: May 14, 2025, 8:28 AM EDT
Protagenic Therapeutics Employees
As of December 31, 2024, Protagenic Therapeutics had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,841,781
Market Cap
1.89M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 2 | 200.00% |
| Dec 31, 2015 | 1 | 0 | - |
| Dec 31, 2014 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PTIX News
- 14 days ago - Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split - Accesswire
- 6 months ago - Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 7 months ago - Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 1 year ago - Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - Accesswire
- 1 year ago - Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit - Accesswire
- 1 year ago - Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Accesswire
- 1 year ago - Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders - Accesswire